I last reviewed Moody's (MCO) in my July 26, 2024 post at which time I considered shares to be richly valued. With the April 22 release of Q1 2025 results and revised FY2025 guidance, I revisit this existing holding. Business Overview Details of MCO's operations are found in Part 1 Item 1 in the FY2024 [...]
I last reviewed CME Group Inc. (CME) in this December 5, 2024 post at which time the Q3 2024 results were the most current. With the release of the Q1 2025 financial results on April 23, 2025, I revisit this existing holding. On April 23, CME entered into a new multi-currency revolving credit facility maturing [...]
In my January 30, 2025 post, I recommended buying undervalued Danaher (DHR) shares amid market challenges. Following that post, shares were caught in the recent broad market pullback. In early April, DHR's share price fell as low as ~$172. Despite a mild recovery to ~$196.50 as I compose this post on April 24, I still [...]
In my November 3, 2024 Thermo Fisher Scientific (TMO) post, I stated 'I think there will be an opportunity to acquire shares at a more favorable valuation within the next 12 months'. TMO shares were trading @ ~$558. Within days of that post, TMO's share price plunged thus contributing to an improvement in its valuation. [...]
A strong case for investing in BlackRock (BLK) can be made when markets implode. It is the world's largest asset manager with over $11.5 TRILLION of Assets Under Management (AUM). In prior Brookfield (BN.to), Blackstone (BX), and BlackRock (BLK) posts, I stated that the asset management industry is saturated and that a 'shake-out' is imminent. [...]
To the best of my ability, I try to provide the timely disclosure of my investment activity. In my April 3 Blackstone and Brookfield Exposure Increase post, I disclose purchases in those two companies. With the April 7 Mastercard (MA), S&P Global (SPGI), and HEICO Corporation (HEI and HEI.a) exposure increases, I now disclose these [...]
We are certainly living in 'interesting times'. As investors, we can either 'panic' or view them as an 'opportunity'. I view the April 2 tariff announcement as an 'opportunity'. A HUGE segment of the global population is, unfortunately, going to be in a 'world of hurt'. The same applies to a great many companies whose [...]
In my December 19, 2024 post I disclose initiating a 300 share Cintas (CTAS) position in one of the 'Side' accounts in the FFJ Portfolio. I subsequently acquired an additional 200 shares on December 31, 2024 thereby bringing my total exposure to 500 shares. Although CTAS is in an entirely different industry than Rollins (ROL), [...]
Following my October 2, 2024 post at which time the most currently available financial information was for Q1 2025, Paychex (PAYX) disclosed its intent to acquire Paycor HCM (PYCR) for ~$4.1B on January 7, 2025. PAYX expects to close this acquisition in April 2025. This impending acquisition makes strategic sense as it enables PAYX to expand [...]
Invest in a business any fool can run, because someday a fool will. Charlie Munger and Warren Buffett - Berkshire Hathaway Nike (NKE) is a good example of how poor leadership can harm even great companies! When John Donahoe was appointed as NKE's 4th CEO in January 2020, NKE called out his 'expertise in digital [...]